Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD Study

Thursday, May 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The Phase 2a HERALD Study demonstrated that ALG-055009, a novel thyroid hormone receptor beta agonist, significantly reduced atherogenic lipids and lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis. This finding highlights the potential of ALG-055009 in addressing lipid-related issues in this patient population.
Price reaction · baseline $4.36 (2025-05-07 close) · hit after-hours · 3 other ALGS headline(s) in the window, move may be shared
day 0 close
+11.7%
day 1
+2.8%
day 3 · peak
+36.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant reductions in atherogenic lipids/lipoproteins observed.
  • Novel thyroid hormone receptor beta agonist shows promise.
  • Study conducted in patients with metabolic dysfunction-associated steatohepatitis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a novel thyroid hormone receptor beta agonist.

What were the results of the HERALD Study?

The study showed significant reductions in atherogenic lipids and lipoproteins.

Who participated in the Phase 2a HERALD Study?

Patients with presumed metabolic dysfunction-associated steatohepatitis participated.

What condition does ALG-055009 target?

It targets lipid-related issues in patients with metabolic dysfunction.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 atherogenic lipids thyroid hormone receptor Phase 2a study metabolic dysfunction
Last updated: May 8, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →